Source: FeedNavigator.com
Embion, a novel bioactives developer, has been awarded a grant of CHF250k (US$276k) from a Swiss public purpose fund, Foundation ALCEA, which it says will help it kick-off a Series A financing round in November.
Swiss microbiome modulation startup looks to investors to scale up
Oct 26, 2020
|In In the Media